Park M, Choi J, Maharub Hossain Fahim M, Asevedo E, Nurkolis F, Ribeiro R
Front Pharmacol. 2025; 16:1504618.
PMID: 40034825
PMC: 11872924.
DOI: 10.3389/fphar.2025.1504618.
Alpoim-Moreira J, Szostek-Mioduchowska A, Slyszewska M, Rebordao M, Skarzynski D, Ferreira-Dias G
Animals (Basel). 2023; 13(7).
PMID: 37048467
PMC: 10093662.
DOI: 10.3390/ani13071212.
Saliba A, John A, Kaufmann S
Cancer Drug Resist. 2021; 4:125-142.
PMID: 33796823
PMC: 8011583.
DOI: 10.20517/cdr.2020.95.
Majchrzak-Celinska A, Warych A, Szoszkiewicz M
Genes (Basel). 2021; 12(2).
PMID: 33572577
PMC: 7911730.
DOI: 10.3390/genes12020208.
Joseph D, Strand D, Vezina C
Am J Clin Exp Urol. 2019; 6(6):197-218.
PMID: 30697577
PMC: 6334199.
Readers of DNA methylation, the MBD family as potential therapeutic targets.
Ginder G, Williams Jr D
Pharmacol Ther. 2017; 184:98-111.
PMID: 29128342
PMC: 6438182.
DOI: 10.1016/j.pharmthera.2017.11.002.
The effect of 5-azacytidine and cytidine analogs onDrosophila melanogaster cells in culture.
Bournias-Vardiabasis N, Buzin C, Reilly J
Wilehm Roux Arch Dev Biol. 2017; 192(5):299-302.
PMID: 28305519
DOI: 10.1007/BF00848664.
Induction of Epigenetic Alteration by CPUK02, An Ent- kaurenoid Derivative of Stevioside.
Mokarram P, Mohammadi Z, Khazayel S, Dayong Z
Avicenna J Med Biotechnol. 2017; 9(1):13-18.
PMID: 28090275
PMC: 5219816.
Profile of Peter A. Jones.
Viegas J
Proc Natl Acad Sci U S A. 2016; 113(48):13546-13548.
PMID: 27872276
PMC: 5137708.
DOI: 10.1073/pnas.1617318113.
Targeting the cancer epigenome for therapy.
Jones P, Issa J, Baylin S
Nat Rev Genet. 2016; 17(10):630-41.
PMID: 27629931
DOI: 10.1038/nrg.2016.93.
Epigenetics and innate immunity: the 'unTolld' story.
Hennessy C, McKernan D
Immunol Cell Biol. 2016; 94(7):631-9.
PMID: 26924642
DOI: 10.1038/icb.2016.24.
Epigenetic memory in the context of nuclear reprogramming and cancer.
Halley-Stott R, Gurdon J
Brief Funct Genomics. 2013; 12(3):164-73.
PMID: 23585580
PMC: 3662891.
DOI: 10.1093/bfgp/elt011.
Epigenetic therapies in MDS and AML.
Griffiths E, Gore S
Adv Exp Med Biol. 2012; 754:253-83.
PMID: 22956506
PMC: 4086806.
DOI: 10.1007/978-1-4419-9967-2_13.
Transformation of human mesenchymal cells and skin fibroblasts into hematopoietic cells.
Harris D, Hazan-Haley I, Coombes K, Bueso-Ramos C, Liu J, Liu Z
PLoS One. 2011; 6(6):e21250.
PMID: 21731684
PMC: 3120836.
DOI: 10.1371/journal.pone.0021250.
Equitoxic doses of 5-azacytidine and 5-aza-2'deoxycytidine induce diverse immediate and overlapping heritable changes in the transcriptome.
Qiu X, Hother C, Ralfkiaer U, Sogaard A, Lu Q, Workman C
PLoS One. 2010; 5(9).
PMID: 20927380
PMC: 2947512.
DOI: 10.1371/journal.pone.0012994.
Effects of a novel DNA methyltransferase inhibitor zebularine on human breast cancer cells.
Billam M, Sobolewski M, Davidson N
Breast Cancer Res Treat. 2009; 120(3):581-92.
PMID: 19459041
PMC: 3901992.
DOI: 10.1007/s10549-009-0420-3.
DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes.
Griffiths E, Gore S
Semin Hematol. 2008; 45(1):23-30.
PMID: 18179966
PMC: 2234265.
DOI: 10.1053/j.seminhematol.2007.11.007.
Stable stem cell commitment to the adipocyte lineage by inhibition of DNA methylation: role of the BMP-4 gene.
Bowers R, Kim J, Otto T, Lane M
Proc Natl Acad Sci U S A. 2006; 103(35):13022-7.
PMID: 16916928
PMC: 1559746.
DOI: 10.1073/pnas.0605789103.
Decitabine: a historical review of the development of an epigenetic drug.
de Vos D, van Overveld W
Ann Hematol. 2005; 84 Suppl 1:3-8.
PMID: 16220311
PMC: 7103145.
DOI: 10.1007/s00277-005-0008-x.
Continuous zebularine treatment effectively sustains demethylation in human bladder cancer cells.
Cheng J, Weisenberger D, Gonzales F, Liang G, Xu G, Hu Y
Mol Cell Biol. 2004; 24(3):1270-8.
PMID: 14729971
PMC: 321446.
DOI: 10.1128/MCB.24.3.1270-1278.2004.
